ABO blood group does not influence Child‐Pugh A cirrhosis outcome: An observational study from CIRRAL and ANRS CO12 CIRVIR cohorts

Non‐O blood group promotes deep vein thrombosis and liver fibrosis in both general population and hepatitis C. We aimed to evaluate the influence of Non‐O group on the outcome of Child‐Pugh A cirrhotic patients.

[1]  G. Tosetti,et al.  AB0, von Willebrand factor/factor VIII and portal vein thrombosis in decompensated cirrhosis: Too late to unmask the culprit? , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[2]  M. Trauner,et al.  The impact of ABO blood type on the prevalence of portal vein thrombosis in patients with advanced chronic liver disease , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[3]  Alihan Oral,et al.  Prognostic role of ABO blood group and Rhesus factor in cirrhotic patients with hepatocellular carcinoma , 2019, Scientific Reports.

[4]  V. de Lédinghen,et al.  Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis. , 2018, Journal of hepatology.

[5]  S. Biggins,et al.  Neutrophil‐to‐Lymphocyte Ratio Associates Independently With Mortality in Hospitalized Patients With Cirrhosis , 2018, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[6]  X. Qi,et al.  ABO blood type and risk of hepatocellular carcinoma: a meta-analysis , 2018, Expert review of gastroenterology & hepatology.

[7]  A. Lebreton,et al.  Increased factor VIII plays a significant role in plasma hypercoagulability phenotype of patients with cirrhosis , 2018, Journal of thrombosis and haemostasis : JTH.

[8]  D. Bauer,et al.  Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity , 2018, Alimentary Pharmacology and Therapeutics.

[9]  L. Christou,et al.  High von Willebrand factor antigen levels and procoagulant imbalance may be involved in both increasing severity of cirrhosis and portal vein thrombosis , 2016, Hepatology.

[10]  P. James,et al.  Aging and ABO blood type influence von Willebrand factor and factor VIII levels through interrelated mechanisms , 2016, Journal of thrombosis and haemostasis : JTH.

[11]  H. Ullum,et al.  ABO Blood Group and Risk of Thromboembolic and Arterial Disease: A Study of 1.5 Million Blood Donors. , 2016, Circulation.

[12]  C. Fondevila,et al.  Nontumoral portal vein thrombosis in patients awaiting liver transplantation , 2016, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[13]  A. Hofman,et al.  Prothrombotic genetic risk factors are associated with an increased risk of liver fibrosis in the general population: The Rotterdam Study. , 2015, Journal of hepatology.

[14]  V. de Lédinghen,et al.  Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort) , 2015, Hepatology.

[15]  S. Chevret,et al.  Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: Results of a longitudinal study , 2015, Hepatology.

[16]  W. Ageno,et al.  ABO Blood Group and Vascular Disease: An Update , 2013, Seminars in Thrombosis & Hemostasis.

[17]  B. Nordestgaard,et al.  Risk of venous thromboembolism and myocardial infarction associated with factor V Leiden and prothrombin mutations and blood type , 2013, Canadian Medical Association Journal.

[18]  E. Gómez,et al.  The natural history of compensated HCV-related cirrhosis: a prospective long-term study. , 2013, Journal of hepatology.

[19]  D. Valla,et al.  Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. , 2012, Gastroenterology.

[20]  W. Ageno,et al.  Non-O Blood Type Is the Commonest Genetic Risk Factor for VTE: Results from a Meta-Analysis of the Literature , 2012, Seminars in Thrombosis & Hemostasis.

[21]  S. Roman,et al.  Noninvasive diagnosis and prognosis of liver cirrhosis: a comparison of biological scores, elastometry, and metabolic liver function tests , 2010, European journal of gastroenterology & hepatology.

[22]  J. O’Donnell,et al.  ABO blood group determines plasma von Willebrand factor levels: a biologic function after all? , 2006, Transfusion.

[23]  P. Böelle,et al.  Association Between ABO Blood Group and Fibrosis Severity in Chronic Hepatitis C Infection , 2006, Digestive Diseases and Sciences.

[24]  P. D. de Groot,et al.  Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity , 2006, Hepatology.

[25]  P. Whincup,et al.  The metabolic syndrome and insulin resistance: relationship to haemostatic and inflammatory markers in older non-diabetic men. , 2005, Atherosclerosis.

[26]  D. Bowen,et al.  An influence of ABO blood group on the rate of proteolysis of von Willebrand factor by ADAMTS13 , 2003, Journal of thrombosis and haemostasis : JTH.

[27]  S. Olliff,et al.  Portal vein thrombosis in adults undergoing liver transplantation: risk factors, screening, management, and outcome. , 2000, Transplantation.

[28]  J. Vandenbroucke,et al.  Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis , 1995, The Lancet.

[29]  V. Arroyo,et al.  Compensated cirrhosis: Natural history and prognostic factors , 1987, Hepatology.